Choose a language and wait for the translated text.
Shots:
Ascletis has submitted an IND application to the US FDA for ASC30_39 FDC, a once-daily oral FDC tablet of small molecule GLP-1R agonist ASC30 & selective amylin receptor agonist ASC39, for obesity
In dogs, ASC30_39 FDC showed high oral bioavailability, high drug exposure & a half-life of up to 12hrs., consistent with the monotherapies; ASC39 was 40-fold selective for hAMY1R over hCTR & reduced body weight by 6.6% (PBO-adjusted) in DIO rats
ASC30 is being evaluated in 2 global P-III (AURORA-1 & AURORA-2) studies in ~4,600 pts with obesity or overweight, with topline data expected in Q3’28
Ref: PR Newswire | Image: Ascletis Pharma | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Ascletis Submits IND Application to the US FDA for ASC30_39 FDC to Treat Obesity appeared first on PharmaShots.
